Edgar Filing: Zhou Rong - Form 4

Zhou Rong Form 4 December 06, 20 FORM 2 Check this bo if no longer subject to Section 16. Form 4 or Form 5 obligations may continue <i>See</i> Instructio 1(b).	06, 2018 M 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 this box onger tto n 16. to Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 20(b) of the Investment Company Act of 1940							OMB Number: Expires: Estimated burden hou response	irs per		
(Print or Type Resp	oonses)										
			2. Issuer Name and Ticker or Trading Symbol Amphastar Pharmaceuticals, Inc. [AMPH]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
			3. Date of Earliest Transaction (Month/Day/Year) 12/03/2018					Director 10% Owner X Officer (give title Other (specify below) below) EVP, Production Center			
RANCHO CUCAMONGA	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)					 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 			
(City)		Cip)	Table	I - Non-De	erivative S	ecuri	ties Aco	quired, Disposed o	f. or Beneficia	llv Owned	
	Transaction Date Month/Day/Year)	2A. Deemed Execution I any (Month/Day	d Date, if	3. Transactic Code (Instr. 8) Code V	4. Securit	ties (A) o of (D	r)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock 12	2/03/2018			S <u>(1)</u>	1,089	D	\$ 22	53,119 <u>(2)</u>	D		
Common Stock								99,668	Ι	See footnote (3)	
Common Stock								5,000	Ι	See footnote (4)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: Zhou Rong - Form 4

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Date	7. Tit Amou Under Secur (Instr	ınt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address		Relationships						
r of the term	Director	10% Owner	Officer	Other				
Zhou Rong C/O AMPHASTAR PHARMACEUTICALS 11570 6TH STREET RANCHO CUCAMONGA, CA 91730	, INC.		EVP, Production Center					
Signatures								
/s/ Eva Wen, by power of 12/0	6/2018							

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2018.
- (2) Includes 905 shares acquired under the Issuer's 2014 Employee Stock Purchase Plan on November 30, 2018.
- (3) The shares are held of record by the Zhou Family Trust for which the reporting person serves as a trustee.
- (4) The shares are held of record by the reporting person's spouse.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.